ArticleEClinicalMedicine2025

Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.

Yue Chi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.